NYSE Analytics 07/03/2014
NYSE Analytics 07/03/2014
Early Market Close 1:00 PM EST
Spyder ETF grows before NYSE opening bell.
SPY (intraday chart) uptrend on premarket. Support 197.00, resistance 197.50.
Gapping up/down: ISCA +4% after earnings, LULU and PCAR +4% on M&A spec; CREE +2% on upgrade; SNX and FUN -1% following earnings/guidance, miners trading lower, RMC -1.6% after dg.
In reaction to strong earnings/guidance: ISCA +4.3%, WAG +0.4%.
Select financial related names showing strength: CS +1.4%, DB +1.3%, BCS +0.8%, UBS +0.8%, RBS+0.6%.
Other news: DRL +32% (cont strength following yesterday’s court appeal win), VRS +23.1% (commences debt exchange offers ), APP +12% (Apparel CEO has given stake to hedge fund, according to reports), ATNY+6% (received new order to supply high-power amplifier systems as part of a DoD maritime requirement),BODY +3.7% (disclosed Richard Walters appointed as CFO, Fred Lamster was appointed to the Board of Directors and named Chairman), LULU +3.6% (founder considering buyout despite hurdles a deal may face, according to reports), PCAR +3.5% (M&A speculation, Volkswagon (VLKAY) has denied that it is bidding for PCAR next year following Daimler (DDAIF) comments, according to reports), RYAAY +2.9% (may be attributed to exec comments suggesting strong June traffic), GSAT +2.3% (cont strength), QTS +1.7% (acquired New Jersey data center from McGraw Hill Financial (MHFI) and formed strategic partnership with ATOS), LITB +1.7% (still checking), RAD +1.5% (trading higher ahead of SSS release), SFLY +1% (cont specluation of M&A), GPRO +1% (continued vol after recent IPO), TSLA +0.9% (following PA store news),VOD +0.9% (Vodafone PLC and ESB to invest EUR 450 million in 100% fibre broadband network across Ireland in European first).
Analyst comments: AERI +4.2% (initiated with a Buy at Canaccord Genuity), CREE +2.6% (upgraded to Outperform from Perform at Oppenheimer), ITMN +1.9% (disclosed that the FDA has acknowledged receipt of the resubmitted Class 2 New Drug Application for pirfenidone, which the Company resubmitted to the FDA on May 23, 2014), TS +1.8% (upgraded to Neutral from Sell at Goldman)
In reaction to disappointing earnings/guidance: SNX -1.3%, FUN -1.2%.
Select metals/mining stocks trading lower:
SSRI -2%, GDX -1%, SLV -0.9%, AG -0.8%, GG -0.7%,ABX -0.7%, GLD -0.6%, KGC -0.5%.
Other news: RGDO -53.7% (announces initiation of DSMB review of REGULATE-PCI data), NQ -17% (announced certain changes to its Board of Directors and provided a status update on its 2013 annual audit),TKMR -14.5% (receives notice of clinical hold for TKM-Ebola Phase I Clinical Trial), BIND -10.7% (announced today the completion of its collaborative research program with Amgen), BIND -10.7% (announced the completion of its collaborative research program with Amgen (AMGN); companies will not be exercising their options to develop an Accurin incorporating the Amgen therapeutic payload), RGSE -9.7% (has entered into a definitive agreement to raise ~$7.0 mln in a private placement financing transaction), USU -5.3% (pulling back following yesterday’s advance), PBR -1.3% (still checking), AZC -0.6% (co and Hudbay Minerals (HBM) announce filing of offer documents for friendly acquisition).
Analyst comments: RMD -1.6% (downgraded to Hold from Buy at Deutsche Bank), RSPP -1.5% (downgraded to Neutral from Buy at UBS), ERIC -1.2% (initiated with a Hold at Jefferies), AZN -0.9% (resumed with a Underweight at JP Morgan).
Trading Ideas NYSE & NASDAQ:
- LULU long above premarket high
- TKMR long above 12.00